scholarly journals Towards pancreatic cancer diagnosis using EIS biochips

Lab on a Chip ◽  
2013 ◽  
Vol 13 (4) ◽  
pp. 730 ◽  
Author(s):  
Maria Serena Chiriacò ◽  
Elisabetta Primiceri ◽  
Anna Grazia Monteduro ◽  
Anna Bove ◽  
Stefano Leporatti ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Diagnosis

Molecular markers in pancreatic cancer diagnosis

2013 ◽  
Vol 418 ◽  
pp. 22-29 ◽  
Author(s):  
Marta Herreros-Villanueva ◽  
Meritxel Gironella ◽  
Antoni Castells ◽  
Luis Bujanda
Keyword(s):  
Pancreatic Cancer ◽  
Molecular Markers ◽  
Cancer Diagnosis

scholarly journals Correction: The Association of Statin Use after Cancer Diagnosis with Survival in Pancreatic Cancer Patients: A SEER-Medicare Analysis

PLoS ONE ◽  
2015 ◽  
Vol 10 (5) ◽  
pp. e0128730 ◽  
Author(s):  
Christie Y. Jeon ◽  
Stephen J. Pandol ◽  
Bechien Wu ◽  
Galen Cook-Wiens ◽  
Roberta A. Gottlieb ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
After Cancer ◽  
Statin Use

scholarly journals Advance in Pancreatic Cancer Diagnosis and Therapy

2020 ◽  
Author(s):  
Xiaojie Cai ◽  
Jie Gao ◽  
Yanfang Liu ◽  
Ming Wang ◽  
Qiulian Ma ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Stem Cells ◽  
Survival Rate ◽  
Tumor Microenvironment ◽  
Cancer Diagnosis ◽  
Treatment Resistance ◽  
Serum Markers ◽  
Molecular Probes ◽  
Cancer Death ◽  
Cancer Diagnosis And Therapy

Pancreatic carcinoma is the fourth leading cause of cancer death in the word wild. Although the advance in treatment this disease, the 5-years survival rate is still rather low. In the recent year, many new therapy and treatment avenues have been developed for pancreatic cancer. In this chapter, we mainly focus on the following aspect: 1) the treatment modality in pancreatic cancer, including chemotherapy, radiotherapy, and immunotherapy; 2) the mechanism of pancreatic cancer treatment resistance, especially in cancer stem cells and tumor microenvironment; 3) the diagnosis tools in pancreatic cancer, including serum markers, imaging methods and endoscopic ultrasonography. Novel molecular probes based on the nanotechnology in the diagnosis of pancreatic cancer are also discussed.

Cancer Survival Is (Mostly) Improving

Pained ◽  
2020 ◽  
pp. 245-246
Author(s):  
Michael D. Stein ◽  
Sandro Galea
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Pancreatic Cancer ◽  
Survival Rate ◽  
Cancer Diagnosis ◽  
Cancer Survival ◽  
Prostate Cancer Screening ◽  
Survival Rates ◽  
The United States ◽  
Cervical Cancers

This chapter discusses how the 5-year survival rates for the most common cancers in the United States improved by nearly 20% since the 1970s. While promising overall, low survival rates persist for pancreatic, liver, lung, esophageal, brain, and many other cancers. Meanwhile, 5-year survival for uterine and cervical cancers worsened. Pancreatic cancer has the lowest 5-year survival rate at 8.2%. In contrast, prostate cancer had the greatest 5-year survival increase from 67.8% to 98.6%, most likely reflecting a substantial uptick in prostate cancer screening and early detection. Five-year survival with leukemia also improved significantly, from 34.2% to 60.6%, likely resulting from improved treatments. As such, in both detection and treatment, the United States is making progress. For the millions of Americans who face a cancer diagnosis, this is cause for hope.

Impact of Pancreatic Cancer and Subsequent Resection on Glycemic Control in Diabetic and Nondiabetic Patients

2011 ◽  
Vol 77 (8) ◽  
pp. 1032-1037 ◽  
Author(s):  
Michael A. White ◽  
Steven C. Agle ◽  
Hannah M. Fuhr ◽  
James H. Mehaffey ◽  
Brett H. Waibel ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Glycemic Control ◽  
Cancer Diagnosis ◽  
Univariate Analysis ◽  
Cell Mass ◽  
University Teaching ◽  
Partial Pancreatectomy ◽  
Onset Diabetes ◽  
Number Of Factors ◽  
New Onset

The incidence of new onset or worsening diabetes is surprisingly low in patients after partial pancreatectomy for cancer, leading us to question what factors predict diminished glycemic control in those undergoing resection. All patients undergoing pancreatectomy for cancer at a large, rural university teaching hospital between 1996 and 2010 were identified. The incidence of new onset, or worsening, existing diabetes was determined based on pre and postoperative medication requirement. Univariate analysis was undertaken to identify factors that predict worsened glycemic control. One hundred and one (1 total, 79 Whipple, 21 distal) patients were identified, 41 per cent of which had preexisting diabetes. Nearly half of existing diabetics manifested an increased medication requirement prior to their cancer diagnosis. New onset diabetes occurred in 20 per cent of postoperative patients. Of established diabetics, 34 per cent had either improved glycemic control (9/41) or were cured (5/41) despite the reduction of islet cell mass that occurred with surgery. On univariate analysis, only prolonged hospitalization was associated with worsened glycemic control. Diminished glycemic control is a frequent presenting symptom of pancreatic cancer. Worsened or new onset diabetes is associated with length of stay, which can be influenced by a number of factors including complications and comorbidities.

scholarly journals Identification of potential microRNA panels for pancreatic cancer diagnosis using microarray datasets and bioinformatics methods

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Roshanak Shams ◽  
Samaneh Saberi ◽  
Mohammadreza Zali ◽  
Amir Sadeghi ◽  
Soudeh Ghafouri-Fard ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Diagnosis ◽  
Microarray Datasets

Does Cholecystectomy Prior to the Diagnosis of Pancreatic Cancer Affect Outcome?

2008 ◽  
Vol 74 (7) ◽  
pp. 602-606 ◽  
Author(s):  
Stephen H. Gray ◽  
Mary T. Hawn ◽  
Meredith L. Kilgore ◽  
Huifeng Yun ◽  
John D. Christein
Keyword(s):  
Pancreatic Cancer ◽  
Weight Loss ◽  
Abdominal Pain ◽  
Early Diagnosis ◽  
Cancer Diagnosis ◽  
Curative Resection ◽  
Tumor Stage ◽  
Seer Database ◽  
Patient Demographics ◽  
Medicare Data

Early diagnosis and curative resection are significant predictors of survival in patients with pancreatic cancer. We hypothesize that cholecystectomy within 12 months of pancreatic cancer affects 1-year survival. The Surveillance Epidemiology and End Result (SEER) database linked to Medicare data was used to identify patients diagnosed with pancreatic cancer who underwent cholecystectomy 1 to 12 months prior to cancer diagnosis. The SEER database identified 32,569 patients from 1995 to 2002; 415 (1.3%) underwent cholecystectomy prior to cancer diagnosis. Patients who underwent cholecystectomy had a higher proportion of diabetes (40.2% vs 20.5%; P < 0.01), obesity (8.9% vs 3.1%; P < 0.01), jaundice (17.3% vs 0.7%; P < 0.01), cholelithiasis (70.4% vs 4.2%; P < 0.01), choledocholithiasis (0.7% vs 0.0%; P < 0.01), weight loss (17.3% vs 4.7%; P < 0.01), abdominal pain (79.5% vs 22.5%), steatorrhea (0.7% vs 0.0%; P < 0.01), and cholecystitis (32.3% vs 1.7%; P < 0.0001). After controlling for tumor stage, patient demographics, and symptoms, survival at 1 year was significantly lower in patients undergoing cholecystectomy (OR, 0.75; 95% CI, 0.58–0.97). Recent cholecystectomy is associated with decreased 1-year survival among patients with pancreatic cancer. For patients older than 65 years of age, further evaluation prior to cholecystectomy may be necessary to exclude pancreatic cancer, especially patients with jaundice, weight loss, and steatorrhea.

scholarly journals Commentary: Blood-Derived microRNAs for Pancreatic Cancer Diagnosis: A Narrative Review and Meta-Analysis

2019 ◽  
Vol 9 ◽  
Author(s):  
Rama Jayaraj ◽  
Chellan Kumarasamy ◽  
Shanthi Sabarimurugan ◽  
Siddhartha Baxi
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Diagnosis ◽  
Meta Analysis ◽  
Narrative Review
Sign in / Sign up

Export Citation Format

Share Document